Home > Press > Advance Nanotech Senior VP to lead biopharma seminar
Advance Nanotech Senior VP to lead biopharma seminar at University of Massachusetts Boston
New York City | Posted on April 25, 2006
Advance Nanotech, Inc., (OTC BB:AVNA.OB - News), the premier provider of financing and support services to expedite the commercialization of nanotechnology discoveries, today announced that Dr. Michael Helmus, senior vice president, BioPharma, will lead a seminar on Monday, April 24 on Commercializing Nanotechnology in BioPharma Applications. The seminar is sponsored by the Biology and Chemistry Departments of the University of Massachusetts, and will take place at the University’s Boston campus.
Who – Dr. Michael Helmus, senior vice president, BioPharma at Advance Nanotech will lead a seminar on Commercializing Nanotechnology in BioPharma Applications. Dr. Helmus currently serves on the University of Massachusetts Boston Science Advisory Board.
What – Spring 2006 Biology Seminar Series.
When – Monday, April 24 at 2:30 pm.
Where – University of Massachusetts, Boston Campus, Science Building, Small Science Auditorium, First Floor, Room S/1/006.
Why – The seminar will explore progress in the uses of nanotechnology in BioPharma Applications.
For more information on the seminar or to schedule a press briefing with Helmus, please contact Derek Brookmeyer at 415.623.2076. For more information about the seminar series, go to www.bio.umb.edu/events.
About Michael Helmus, Ph.D.
Dr. Helmus assumed the position of senior vice president, BioPharma at Advance Nanotech in August 2005. Dr. Helmus is responsible for managing all of the firm’s partnerships and investments related to the biopharma and life sciences fields. Before joining Advance Nanotech Dr. Helmus served as the Vice President, Advanced Biomaterials at Boston Scientific. Prior to that Dr. Helmus held research and development positions with organizations including Edwards Lifesciences, Baxter CVS, Pfizer, and Arthur D. Little. Dr. Helmus holds a PhD and an MS in Biomedical Engineering from Case Western Reserve University and a BS in Metallurgy and Materials Science from Lehigh University. Dr. Helmus’ expertise includes the identification and acquisition of new technologies, implementation and management of research and development programs, and intellectual property development and management. In the course of his career Dr. Helmus has been issued 26 U.S. patents, authored 47 technical publications and written 29 technology and market assessments.
About Advance Nanotech:
Advance Nanotech is dedicated to the successful commercialization of disruptive nanotechnologies to produce nano-enabled products. Advance provides financing and support services including commercialization guidance, project and infrastructure management, leadership assets, and counsel on intellectual property, licensing and regulatory issues to ensure maximum market potential. Advance Nanotech's diversified portfolio of 26 nanotechnologies, of which the company holds a majority stake in 21, impacts a range of applications including, but not limited to, sensors, medical therapeutics and composites. Advance is forging partnerships with leading manufacturers and universities in Europe, Asia and North America to transform innovative nanotechnology concepts into practical solutions.
For more information, please click here.
This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.
Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech 's dependence on third parties and partners; and those risks described Advance Nanotech 's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.
Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.
One Embarcadero Center, Suite 500
San Francisco, CA 94111
Copyright © Advance Nanotech
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014
Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014
Nanoparticle technology triples the production of biogas October 23rd, 2014
SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014
Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014
Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014